Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: ImmuPharma plc

Market Cap 26.83M 35.4M 31.1M 28.66M 50.26M 3.35B 51.11M 344M 133M 1.65B 133M 130M 5.72B P/E 2024
-2.01x
P/E 2025 -16.8x
Enterprise Value 25.48M 33.62M 29.53M 27.21M 47.73M 3.18B 48.54M 327M 126M 1.56B 126M 123M 5.43B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
94.99%
Yield 2024 *
-
Yield 2025 -
1 day-4.65%
1 week-10.87%
Current month-4.65%
1 month-8.89%
3 months-16.33%
6 months-28.07%
Current year-33.87%
1 week 4.1
Extreme 4.1
5
1 month 4.1
Extreme 4.1
5.5
Current year 4
Extreme 4
11
1 year 1.39
Extreme 1.3861
19.4
3 years 0.82
Extreme 0.822
19.4
5 years 0.82
Extreme 0.822
19.4
10 years 0.82
Extreme 0.822
193.74
Manager TitleAgeSince
Chief Executive Officer 70 2021-07-29
Director of Finance/CFO - 2024-12-02
Chief Tech/Sci/R&D Officer - 2025-08-31
Director TitleAgeSince
Director/Board Member 60 2021-07-28
Chairman 70 2015-09-29
Director/Board Member 62 2021-07-15
Date Insider Type Main position Quantity % Market Cap.
24-04-18Free

Director

3,000,000 0.7204%
24-04-18Free

Director

2,000,000 0.4803%
22-12-21Free

Chief Executive Officer

1,800,000 0.5399%
Change 5-day change 1-year change 3-year change Capi.($)
-4.65%-10.87%+77.11%+74.84% 35.56M
+2.96%+4.21%-8.16%-2.76% 43.24B
+1.53%+7.16%+319.06%+557.48% 35.25B
+0.84%+4.28%+6.87%+53.51% 30.22B
+2.34%-4.24%+10.57%-19.85% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+2.40%+1.04% - - 14.16B
+2.88%+1.15%+51.28%+109.01% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+0.63%+4.50%+102.76%+92.68% 12.54B
Average +0.65%-0.93%+63.67%+99.34% 21.32B
Weighted average by Cap. +1.20%-0.72%+68.17%+119.08%

Financials

2024 2025
Net sales - -
Net income -2.48M -3.28M -2.88M -2.65M -4.65M -310M -4.73M -31.85M -12.33M -152M -12.3M -12.04M -529M -1.81M -2.39M -2.1M -1.93M -3.39M -226M -3.44M -23.19M -8.98M -111M -8.95M -8.76M -385M
Net Debt -237K -313K -275K -253K -444K -29.61M -451K -3.04M -1.18M -14.53M -1.17M -1.15M -50.5M -1.35M -1.78M -1.57M -1.44M -2.53M -169M -2.58M -17.34M -6.71M -82.94M -6.7M -6.55M -288M
Logo ImmuPharma plc
ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Employees
7
Date Price Change Volume
26-06-23 GBX 4.100 -4.65% 1,605,416
26-06-22 GBX 4.300 -2.38% 1,772,308
26-06-19 GBX 4.405 0.00% 1,898,513
26-06-18 GBX 4.405 -2.33% 816,463
26-06-17 GBX 4.510 -1.96% 2,072,719
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!